原著論文1
Nishizawa K, Oguma A, Kawata M, et al.
Efficacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphodiesterase 4D-interacting protein.
J Virol
, 88
(8)
, 4083-4099
(2014)
doi: 10.1128/JVI.03775-13.
原著論文2
Kobayashi A, Matsuura Y, Mohri S, et al.
Distinct origins of dura mater graft-associated Creutzfeldt-Jakob disease: past and future problems.
Acta Neuropathol Commun
, 2
(32)
(2014)
doi: 10.1186/2051-5960-2-32.
原著論文3
Kimura T, Nishizawa K, Oguma A, et al.
Secretin receptor involvement in prion-infected cells and animals.
FEBS Lett
, 589
(15)
, 2011-2018
(2015)
doi: 10.1016/j.febslet.2015.05.039.
原著論文4
Hamanaka T, Nishizawa K, Sakasegawa Y, et al.
Structure-activity analysis and antiprion mechanism of isoprenoid compounds.
Virology
, 486
, 63-70
(2015)
doi: 10.1016/j.virol.2015.09.002.
原著論文5
Kobayashi A, Parchi P, Yamada M, et al.
Transmission properties of atypical Creutzfeldt-Jakob disease: a clue to disease etiology?
J Virol
, 89
(7)
, 3939-3946
(2015)
doi: 10.1128/JVI.03183-14.
原著論文6
Kobayashi A, Teruya K, Matsuura Y, et al.
The influence of PRNP polymorphisms on human prion disease susceptibility: an update.
Acta Neuropathol
, 130
(2)
, 159-170
(2015)
doi: 10.1007/s00401-015-1447-7.
原著論文7
Kobayashi A, Matsuura Y, Iwaki T, et al.
Sporadic Creutzfeldt-Jakob Disease MM1+2C and MM1 are Identical in Transmission Properties.
Brain Pathol
, 26
(1)
, 95-101
(2016)
doi: 10.1111/bpa.12264.
原著論文8
Kobayashi A, Parchi P, Yamada M, et al.
Neuropathological and biochemical criteria to identify acquired Creutzfeldt-Jakob disease among presumed sporadic cases.
Neuropathology
, 36
(3)
, 305-310
(2016)
doi: 10.1111/neup.12270.
原著論文9
Teruya K, Oguma A, Nishizawa K, et al.
A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in Rodents.
PLoS Pathog
, 12
(12)
, e1006045-
(2016)
doi: 10.1371/journal.ppat.1006045.
原著論文10
Hamanaka T, Nishizawa K, Sakasegawa Y, et al.
Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.
J Virol
, 91
(6)
, e01862-16-
(2017)
doi: 10.1128/JVI.01862-16.
原著論文11
Teruya K, Doh-ura K.
Insights from Therapeutic Studies for PrP Prion Disease.
Cold Spring Harb Perspect Med
, 7
(3)
, a024430-
(2017)
doi: 10.1101/cshperspect.a024430.
原著論文12
Teruya K, Oguma A, Nishizawa K, et al.
Pyrene conjugation and spectroscopic analysis of hydroxypropyl methylcellulose compounds successfully demonstrated a local dielectric difference associated with in vivo anti-prion activity.
PLoS One
, 12
(9)
, e0185357-
(2017)
doi: 10.1371/journal.pone.0185357.
原著論文13
Munesue Y, Shimazaki T, Qi Z, et al.
Development of a quick bioassay for the evaluation of transmission properties of acquired prion diseases.
Neurosci Lett
, 668
, 43-47
(2018)
doi: 10.1016/j.neulet.2018.01.014.
原著論文14
Kobayashi A, Matsuura Y, Takeuchi A, et al.
A domain responsible for spontaneous conversion of bank vole prion protein.
Brain Pathol
, 29
(2)
, 155-163
(2019)
doi: 10.1111/bpa.12638.
原著論文15
Kobayashi A, Qi Z, Shimazaki T, et al.
Ganglioside Synthase Knockout Reduces Prion Disease Incubation Time in Mouse Models.
Am J Pathol
, 189
(3)
, 677-686
(2019)
doi: 10.1016/j.ajpath.2018.11.009.
原著論文16
Kobayashi A, Iwasaki Y, Takao M, et al.
A Novel Combination of Prion Strain Co-Occurrence in Patients with Sporadic Creutzfeldt-Jakob Disease.
Am J Pathol
, 189
(6)
, 1276-1283
(2019)
doi: 10.1016/j.ajpath.2019.02.012.
原著論文17
Teruya K, Nishizawa K, Oguma A, et al.
Intermolecular crosslinking of abnormal prion protein is efficiently induced by a primuline-sensitized photoreaction.
Biochim Biophys Acta Gen Subj
, 1863
(2)
, 384-394
(2019)
doi: 10.1016/j.bbagen.2018.11.008.
原著論文18
Nishizawa K, Teruya K, Oguma A, et al.
Preparation and Characterization of Cellulose Ether Liposomes for the Inhibition of Prion Formation in Prion-Infected Cells.
J Pharm Sci
, in press-
(2019)
doi: 10.1016/j.xphs.2019.03.025.
